Schroder Investment Management Group increased its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 86.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 805,445 shares of the specialty pharmaceutical company's stock after purchasing an additional 374,213 shares during the quarter. Schroder Investment Management Group owned 1.63% of KalVista Pharmaceuticals worth $6,758,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. boosted its holdings in shares of KalVista Pharmaceuticals by 24.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock worth $87,000 after purchasing an additional 2,043 shares during the period. SG Americas Securities LLC increased its stake in shares of KalVista Pharmaceuticals by 10.0% in the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company's stock worth $123,000 after acquiring an additional 1,319 shares in the last quarter. Intech Investment Management LLC purchased a new position in shares of KalVista Pharmaceuticals during the third quarter valued at approximately $126,000. AlphaQuest LLC boosted its holdings in KalVista Pharmaceuticals by 17.1% in the fourth quarter. AlphaQuest LLC now owns 17,700 shares of the specialty pharmaceutical company's stock worth $150,000 after acquiring an additional 2,588 shares in the last quarter. Finally, Paloma Partners Management Co bought a new position in KalVista Pharmaceuticals in the 3rd quarter worth about $208,000.
KalVista Pharmaceuticals Trading Up 4.8 %
Shares of NASDAQ:KALV traded up $0.50 during trading on Wednesday, reaching $10.82. The company's stock had a trading volume of 1,263,414 shares, compared to its average volume of 399,659. The stock has a market capitalization of $537.93 million, a PE ratio of -2.97 and a beta of 0.39. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.30 and a 12 month high of $15.50. The firm's 50 day simple moving average is $11.01 and its two-hundred day simple moving average is $10.28.
Insider Transactions at KalVista Pharmaceuticals
In related news, CEO Benjamin L. Palleiko sold 6,669 shares of the business's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $11.97, for a total value of $79,827.93. Following the completion of the transaction, the chief executive officer now owns 287,811 shares of the company's stock, valued at $3,445,097.67. The trade was a 2.26 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Paul K. Audhya sold 3,125 shares of KalVista Pharmaceuticals stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total value of $30,687.50. Following the completion of the transaction, the insider now owns 100,334 shares in the company, valued at $985,279.88. This represents a 3.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have purchased 236,055 shares of company stock worth $2,162,146 and have sold 17,292 shares worth $184,625. Company insiders own 10.50% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research firms have commented on KALV. Bank of America initiated coverage on KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a "buy" rating and a $22.00 target price for the company. JMP Securities started coverage on shares of KalVista Pharmaceuticals in a research report on Friday, January 31st. They issued an "outperform" rating and a $19.00 price target on the stock. TD Cowen assumed coverage on KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They set a "buy" rating and a $30.00 price objective for the company. Citizens Jmp raised shares of KalVista Pharmaceuticals to a "strong-buy" rating in a report on Friday, January 31st. Finally, Jones Trading reiterated a "buy" rating and set a $30.00 price objective on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $24.83.
Get Our Latest Stock Report on KALV
About KalVista Pharmaceuticals
(
Free Report)
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
Featured Stories
Before you consider KalVista Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KalVista Pharmaceuticals wasn't on the list.
While KalVista Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
